Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
milestones that CEO Doug Love described as setting up 2026 as a “pivotal year” for the company. Love highlighted two registration-stage programs—ANX007 in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) and ANX005 in Guillain-Barré syndrome (GBS)—alongside a proof-of-concept effort for oral small molecule ANX1502. Love said Annexon's scientific approach centers on inhibiting C1q, which initiates the classical complement pathway and is implicated in harmful inflammation across multiple neuroinflammatory diseases. He contrasted this upstream strategy with “downstream first-generation approaches” targeting C3 and C5, which he said provide incomplete protection against inflammation. Annexon's portfolio includes compartment-specific approaches: ANX005 is designed to block C1q systemically (and in the brain), ANX007 selectively targets C1q in the eye, and ANX1502 is an oral candidate intended to inhibit the classical pathway in systemic autoimmune setti
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon (NASDAQ:ANNX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026GlobeNewswire
- Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré SyndromeGlobeNewswire
- Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ANNX
Earnings
- 11/10/25 - Miss
ANNX
Sec Filings
- 1/14/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/2/26 - Form 4
- ANNX's page on the SEC website